These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19786146)

  • 1. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.
    Thacker EE; Nakayama M; Smith BF; Bird RC; Muminova Z; Strong TV; Timares L; Korokhov N; O'Neill AM; de Gruijl TD; Glasgow JN; Tani K; Curiel DT
    Vaccine; 2009 Nov; 27(50):7116-24. PubMed ID: 19786146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells.
    Hillebrand RM; Vogt A; Strassburg CP; Gonzalez-Carmona MA; Schmidt-Wolf IGH
    Anticancer Res; 2019 Sep; 39(9):4643-4652. PubMed ID: 31519562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells.
    Kim YS; Kim YJ; Lee JM; Han SH; Ko HJ; Park HJ; Pereboev A; Nguyen HH; Kang CY
    Hum Gene Ther; 2010 Dec; 21(12):1697-706. PubMed ID: 20604681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
    Kikuchi T; Moore MA; Crystal RG
    Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system.
    Korokhov N; Noureddini SC; Curiel DT; Santegoets SJ; Scheper RJ; de Gruijl TD
    Mol Pharm; 2005; 2(3):218-23. PubMed ID: 15934782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
    Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
    Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
    Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
    J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
    Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG
    Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN.
    Korokhov N; de Gruijl TD; Aldrich WA; Triozzi PL; Banerjee PT; Gillies SD; Curiel TJ; Douglas JT; Scheper RJ; Curiel DT
    Cancer Biol Ther; 2005 Mar; 4(3):289-94. PubMed ID: 15753654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
    Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
    Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
    Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
    J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule.
    Pereboev AV; Nagle JM; Shakhmatov MA; Triozzi PL; Matthews QL; Kawakami Y; Curiel DT; Blackwell JL
    Mol Ther; 2004 May; 9(5):712-20. PubMed ID: 15120332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically targeted adenovirus vector directed to CD40-expressing cells.
    Belousova N; Korokhov N; Krendelshchikova V; Simonenko V; Mikheeva G; Triozzi PL; Aldrich WA; Banerjee PT; Gillies SD; Curiel DT; Krasnykh V
    J Virol; 2003 Nov; 77(21):11367-77. PubMed ID: 14557622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.
    Lotem M; Zhao Y; Riley J; Hwu P; Morgan RA; Rosenberg SA; Parkhurst MR
    J Immunother; 2006; 29(6):616-27. PubMed ID: 17063124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
    Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
    Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
    Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
    Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.